Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    evolocumab on vascular function
Previous Study | Return to List | Next Study

Effect of Evolocumab on Vascular Function (EVO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03626831
Recruitment Status : Not yet recruiting
First Posted : August 13, 2018
Last Update Posted : October 12, 2018
Sponsor:
Information provided by (Responsible Party):
Roland E. Schmieder, University of Erlangen-Nürnberg Medical School

Brief Summary:

This is a phase IV, randomized (1:1), prospective, double-blind, placebo controlled, parallel-group, single center study at the Clinical Research Unit (CRC) of the Department of Nephrology and Hypertension, with its two separate locations:

  • Nürnberg, Kreuzburger Str. 2, 90471 Nürnberg, and
  • Erlangen, Ulmenweg 18, 91054 Erlangen

The results of this study provide strong support for the concept that it is lower LDL-C levels that is key to achieving better outcomes, and that it is possible to achieve these on top of statin therapy (despite the much debated potential "pleiotropic" effects of statins).

At least 65 patients will be randomized (1:1) and included (informed consent) in order to obtain 58 fully evaluable subjects (29 with evolocumab, 29 with placebo).

Patients will be simultaneously recruited from investigator's outpatient clinics, referring physicians, and advertisement in local newspapers, and social media. Those patients that appear to potentially fulfill the inclusion criteria will be invited to a screening visit. After providing informed consent, patients will be tested for inclusion/exclusion criteria and for feasibility of vascular measurements (in particular to ensure that adequate imaging of the brachial artery is possible). Patients will provide a blood sample for laboratory testing. If the patient then fulfills inclusion criteria and in the absence of exclusion criteria, the patient will be enrolled into the trial, and the study visits will be scheduled. Randomization will take place at the latest one day prior to the study visit 2 (e.g. at the latest at visit 2a).

At visit 2, baseline vascular function parameters will be obtained and the patient will be given an SC injection of the study drug (either SC 420 mg evolocumab or SC placebo). At visit 4, the second injection of study drug will be administered. After 1, 4 and 8 weeks of treatment (visits 3, 4 and 5), testing of vascular function will be repeated. At visit 6, a final close out visits will be performed to gather additional safety information.


Condition or disease Intervention/treatment Phase
Atherosclerotic Cardiovascular Disease Drug: Evolocumab Prefilled Syringe Drug: Placebos Phase 4

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 65 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: randomized (1:1), prospective, double-blind, placebo controlled, parallel-group
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: double blind
Primary Purpose: Treatment
Official Title: Randomized, Double-blind, Placebo Controlled, Parallel-group, Prospective Clinical Study to Analyse the Effect of Evolocumab on Vascular Function
Estimated Study Start Date : November 1, 2018
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : August 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Evolocumab

Arm Intervention/treatment
Active Comparator: Treatment
Baseline vascular function parameters will be obtained and the patient will be given an SC injection of the study drug by Evolocumab Prefilled Syringe (1x SC 420 mg evolocumab).
Drug: Evolocumab Prefilled Syringe
Injection of study drug

Placebo Comparator: Placebo
Baseline vascular function parameters will be obtained and the patient will be given an SC injection of Placebos (1x SC Placebo).
Drug: Placebos
Injection of placebo




Primary Outcome Measures :
  1. Percent change of FMD [ Time Frame: 8 weeks ]
    Percent change of FMD (UNEX EF) after 8 weeks of treatment from baseline


Secondary Outcome Measures :
  1. Absolute change of FMD (UNEX EF) [ Time Frame: 8 weeks ]
    Absolute change of FMD (UNEX EF) after 8 weeks of treatment from baseline

  2. Absolute change of L-FMC [ Time Frame: 8 weeks ]
    Absolute change of L-FMC after treatment from baseline and across all visits

  3. Percent change of L-FMC [ Time Frame: 8 weeks ]
    Percent change of L-FMC after treatment from baseline and across all visits

  4. Absolute change of combined FMD+L-FMC (UNEX EF) [ Time Frame: 8 weeks ]
    Absolute change of combined FMD+L-FMC (UNEX EF) after treatment from baseline and across all visits.

  5. Percent change of combined FMD+L-FMC (UNEX EF) [ Time Frame: 8 weeks ]
    Percent change of combined FMD+L-FMC (UNEX EF) after treatment from baseline and across all visits.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent in written form
  • Male or female 40 - 80 years
  • History of clinically evident atherosclerotic cardiovascular disease as evidenced by ANY of the following:
  • diagnosis of coronary artery disease as evidenced by acute coronary syndrome, myocardial infarction (MI), coronary stent implantation, coronary stenosis ≥50% by coronary angiography
  • diagnosis of non-hemorrhagic stroke or transient ischemic attack (TIA)
  • symptomatic peripheral arterial disease (PAD), as evidenced by intermittent claudication with ankle-brachial index (ABI) < 0.85, or peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease, or artery stenosis ≥50% by angiography
  • Fasting LDL-C ≥ 70 mg/dL (≥ 1.8 mmol/L) or non-HDL-C ≥ 100 mg/dL (≥ 2.6mmol/L) on optimized background lipid lowering therapy (please see Appendix 14.3.)
  • Stable background lipid lowering therapy for at least 4 weeks (please see Appendix 14.3)
  • Most recent fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L) by central laboratory before randomization

Exclusion Criteria:

  • Inability to image the brachial artery and to perform FMD
  • Subjects with statin intolerance
  • Known or suspected homozygous familial hypercholesterolemia (FH)
  • Subject must not be randomized within 4 weeks of their most recent MI or stroke
  • NYHA class III or IV, or last known left ventricular ejection fraction < 30%
  • Atrial fibrillation
  • Known hemorrhagic stroke at any time
  • Uncontrolled or recurrent ventricular tachycardia
  • Planned or expected cardiac surgery or revascularization within 3 months after randomization
  • Uncontrolled hypertension defined as sitting pSBP > 180 mmHg or pDBP > 110 mmHg
  • Use of cholesteryl ester transfer protein (CETP) inhibition treatment, mipomersen, or lomitapide within 12 months prior to randomization. Fenofibrate therapy must be stable for at least 6 weeks prior to final screening at a dose that is appropriate for the duration of the study in the judgment of the investigator. Other fibrate therapy (and derivatives) are prohibited
  • Prior use of PCSK9 inhibition treatment other than evolocumab or use of evolocumab < 12 weeks prior to final lipid screening
  • Untreated or inadequately treated hyperthyroidism or hypothyroidism as defined by thyroid stimulating hormone (TSH) < lower limit of normal (LLN) or > 1.5 times the upper limit of normal (ULN), respectively, and free thyroxine (T4) levels that are outside normal range at final screening
  • Severe renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2 at final screening
  • Active liver disease or hepatic dysfunction, defined as serum Glutamate-Oxaloacetate-Transaminase (SGOT) or serum Glutamate-Pyruvate-Transaminase (SGPT)> 3 times the ULN as determined by central laboratory analysis at final screening
  • Recipient of any major organ transplant (eg, lung, liver, heart, bone marrow, renal)
  • Personal or family history of hereditary muscular disorders
  • LDL or plasma apheresis within 12 months prior to randomization
  • Severe, concomitant non-CV disease that is expected to reduce life expectancy to less than 3 years
  • Creatinine Kinase (CK) > 5 times the ULN at final screening
  • Known major active infection or major hematologic, renal, metabolic, gastrointestinal or endocrine dysfunction in the judgment of the investigator
  • Malignancy (except non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in situ, or stage 1 prostate carcinoma) within the last 10 years
  • Subject has received drugs via a systemic route that have known major interactions with background statin therapy (see Appendix 14.4.) within 1 month prior to randomization or is likely to require such treatment during the study period
  • Currently enrolled in another investigational device or drug study, or less than 30 days since ending another investigational device or drug study(s), or less than 5 fold of half-live time of the investigational drug, or receiving other investigational agent(s)
  • Female subject who has either (1) not used acceptable method(s) of birth control for at least 1 month prior to screening or (2) is not willing to use such a method during treatment with IP and for an additional 15 weeks after the end of treatment with IP, unless the subject is sterilized or postmenopausal;

    • menopause is defined as 12 months of spontaneous and continuous amenorrhea in a female ≥ 55 years old or 12 months of spontaneous and continuous amenorrhea with a follicle-stimulating hormone (FSH) level > 40 IU/L (or according to the definition of "postmenopausal range" for the laboratory involved) in a female < 55 years old unless the subject has undergone bilateral oophorectomy
    • acceptable methods of preventing pregnancy include not having intercourse, birth control pills, injections, implants, or patches, intrauterine devices (IUDs), tubal ligation/occlusion, sexual activity with a male partner who has had a vasectomy, condom or occlusive cap (diaphragm or cervical/vault caps) used with spermicide
  • Subject is pregnant or breast feeding, or planning to become pregnant or to breastfeed during treatment with IP and/ or within 15 weeks after the end of treatment with IP
  • Known sensitivity to any of the active substances or their excipients to be administered during dosing
  • Subject likely to not be available to complete all protocol-required study visits or procedures, to the best of the subject's and investigator's knowledge

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03626831


Contacts
Layout table for location contacts
Contact: Roland E Schmieder, MD +49 9131 85 ext 36245 roland.schmieder@uk-erlangen.de

Locations
Layout table for location information
Germany
Clinical Research Center, Department of Nephrology and Hypertension, University of Erlangen-Nuremberg
Erlangen, Germany, 91054
Sponsors and Collaborators
University of Erlangen-Nürnberg Medical School
Investigators
Layout table for investigator information
Principal Investigator: Roland E Schmieder, MD University Hospital Erlangen

Layout table for additonal information
Responsible Party: Roland E. Schmieder, Full Professor of Medicine, University of Erlangen-Nürnberg Medical School
ClinicalTrials.gov Identifier: NCT03626831     History of Changes
Other Study ID Numbers: CRC2017EVO
First Posted: August 13, 2018    Key Record Dates
Last Update Posted: October 12, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Roland E. Schmieder, University of Erlangen-Nürnberg Medical School:
CVD
LDL
heart failure
PCSK9
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Atherosclerosis
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Evolocumab
Antibodies, Monoclonal
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Immunologic Factors
Physiological Effects of Drugs